The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.
Commentary|Articles|July 16, 2026
Experts Unpack Crucial Hematologic Oncology Data From ASCO 2026
Author(s)Chris Ryan
Fact checked by: Riley Kandel
Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.
Advertisement
Advertisement
At the
Related to this article
The supplemental new drug application was submitted under the accelerated approval pathway with a request for priority review.
The FDA approved ropeginterferon alfa-2b for the treatment of essential thrombocythemia.
The FDA approved daraxonrasib for pancreatic cancer, cleared zanidatamab-based regimens for HER2-positive gastric cancer, and more.
The selective ROCK2 inhibitor TDI01 generated organ-wide responses in previously treated moderate-to-severe chronic graft-versus-host disease, with the 400-mg dose performing best.
The FDA approved rusfertide for the treatment of patients with polycythemia vera.
Patient-reported QOL and symptom outcomes were similar between belzutifan plus lenvatinib and cabozantinib in previously treated RCC.
Dosing adjustments of ponatinib based on responses increased tolerability in patients with chronic myeloid leukemia according to OPTIC.
Advertisement
Advertisement